William Maughan
Stock Analyst at Canaccord Genuity
(2.96)
# 1,313
Out of 4,825 analysts
24
Total ratings
54.17%
Success rate
56.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $102.51 | +67.24% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $4.11 | +337.96% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $10.86 | +286.74% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $5.30 | +201.89% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $9.09 | +560.07% | 1 | Jul 6, 2022 |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $102.51
Upside: +67.24%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $4.11
Upside: +337.96%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $10.86
Upside: +286.74%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $5.30
Upside: +201.89%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $9.09
Upside: +560.07%